Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Human Papillomavirus Infections Therapeutics Market Clinical Trials H2 2014 Review Research Report


News provided by

ReportsnReports

25 Feb, 2015, 10:15 GMT

Share this article

Share toX

Share this article

Share toX

DALLAS, February 25, 2015 /PRNewswire/ --

ReportsnReports.com adds "Human Papillomavirus Infections Global Clinical Trials Review, H2, 2014" to its store. This report provides data on clinical trial scenario of the Human Papillomavirus Infections.

The clinical trial report "Human Papillomavirus Infections Global Clinical Trials Review, H2, 2014″ provides data on the Human Papillomavirus Infections clinical trial scenario. Human Papillomavirus Infections is the most common sexually transmitted infection. It is an infection that is passed between people through skin-to-skin contact. High-risk Human Papillomavirus infection accounts for approximately 5 percent of all cancers worldwide. In the majority of cases, HPV infection has no noticeable signs or symptoms. Signs and symptoms are genital warts, common warts, plantar warts and flat warts. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Human Papillomavirus Infections. This report also provide data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report also includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Companies discussed in this clinical trials report includes Merck & Co., Inc., GlaxoSmithKline plc, Medicis Pharmaceutical Corporation, BioMAS Ltd., AstraZeneca PLC, Novartis AG, MediGene AG, Meda AB, Genticel S.A., G&E Herbal Biotechnology Co., Ltd.

This report also includes the clinical trial overview of top institutes and government that includes The National Institute of Allergy and Infectious Diseases, National Cancer Institute, Johns Hopkins University, University of Pittsburgh, The University of Hong Kong, Leiden University Medical Center, Medical University of Vienna, AIDS Malignancy Clinical Trials Consortium, The Alfred Hospital, The University of Sydney. Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=320860 . (This is a premium report priced at US$2500 for a single user License.)

Featured News & Press Releases cover by this report include: Nov 18, 2014: Researchers Pioneer New Approach To Treating HPV-Related Cervical Cancer; Nov 13, 2014: Genticel completes ProCervix Phase II study enrollment ahead of schedule; Nov 04, 2014: Cevira data published in American Journal of Obstetrics & Gynecology; Oct 30, 2014: Genexine's HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial; Oct 10, 2014: Results of the Cevira Phase 2b presented at DGGG 35
Oct 08, 2014: Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine; Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers.

Reasons to buy 

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

More related reports on Clinical Trials:

Human Papillomavirus Infections - Pipeline Review, H2 2014 

This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects.

Companies discussed in this Onchocerciasis (River Blindness) clinical trials report include Merck & Co., Inc., Takeda Pharmaceutical Company Limited, MediGene AG, Chong Kun Dang Pharmaceutical Corp., Crucell N.V., Starpharma Holdings Limited, Bharat Biotech International Limited, FluGen, Inc., Genticel, Vaxart, Inc., Selecta Biosciences, Inc., Spider Biotech, Indian Immunologicals Limited, Beijing Minhai Biotechnology Co., Ltd, Shanghai Zerun Biotechnology Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Immunservice GmbH, Redbiotec AG, Agilvax, Inc., Nielsen Biosciences, Inc. Complete report available @ http://www.reportsnreports.com/reports/311349-human-papillomavirus-infections-pipeline-review-h2-2014.html .

HIV-2 Infection Global Clinical Trials Review, H2, 2014 

This report provides elemental information and data relating to the clinical trials on HIV-2 Infection. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating HIV-2 Infection. Companies and Institutes discussed in this report includes GlaxoSmithKline plc, Merck & Co., Inc, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., C. H. Boehringer Sohn AG & Co. KG, Abbott Laboratories, AbbVie Inc., BioCryst Pharmaceuticals, Inc., The National Institute of Allergy and Infectious Diseases, French National Agency for Research on AIDS and Viral Hepatitis, University of California, San Francisco, Centers for Disease Control and Prevention, National Center for Complementary and Alternative Medicine, Emory University, University of Washington, Hospital Clinic de Barcelona, University of Miami, Stanford University. Complete report details @ http://www.reportsnreports.com/reports/320859-hiv-2-infection-global-clinical-trials-review-h2-2014.html .

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/u/0/111656568937629536321/posts  

Twitter: http://twitter.com/marketsreports

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

RSS / Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@reportsandreports.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.